DE69431107T2 - Die erzeugung von toleranz gegen fremdtransplantate durch tolerogenese mit hilfe von ersatzlebewesen - Google Patents

Die erzeugung von toleranz gegen fremdtransplantate durch tolerogenese mit hilfe von ersatzlebewesen

Info

Publication number
DE69431107T2
DE69431107T2 DE69431107T DE69431107T DE69431107T2 DE 69431107 T2 DE69431107 T2 DE 69431107T2 DE 69431107 T DE69431107 T DE 69431107T DE 69431107 T DE69431107 T DE 69431107T DE 69431107 T2 DE69431107 T2 DE 69431107T2
Authority
DE
Germany
Prior art keywords
cells
surrogate
pct
organ graft
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69431107T
Other languages
English (en)
Other versions
DE69431107D1 (de
Inventor
William E Beschorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ximerex Inc
Original Assignee
Ximerex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ximerex Inc filed Critical Ximerex Inc
Publication of DE69431107D1 publication Critical patent/DE69431107D1/de
Application granted granted Critical
Publication of DE69431107T2 publication Critical patent/DE69431107T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Transplanting Machines (AREA)
DE69431107T 1993-05-24 1994-05-24 Die erzeugung von toleranz gegen fremdtransplantate durch tolerogenese mit hilfe von ersatzlebewesen Expired - Fee Related DE69431107T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6537093A 1993-05-24 1993-05-24
PCT/US1994/005844 WO1994027622A1 (en) 1993-05-24 1994-05-24 Surrogate tolerogenesis for the development of tolerance to xenografts

Publications (2)

Publication Number Publication Date
DE69431107D1 DE69431107D1 (de) 2002-09-05
DE69431107T2 true DE69431107T2 (de) 2003-03-27

Family

ID=22062242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431107T Expired - Fee Related DE69431107T2 (de) 1993-05-24 1994-05-24 Die erzeugung von toleranz gegen fremdtransplantate durch tolerogenese mit hilfe von ersatzlebewesen

Country Status (8)

Country Link
US (1) US6060049A (de)
EP (1) EP0700297B1 (de)
JP (1) JP4236279B2 (de)
AT (1) ATE221382T1 (de)
AU (1) AU693452B2 (de)
CA (1) CA2163517C (de)
DE (1) DE69431107T2 (de)
WO (1) WO1994027622A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220007A1 (en) * 1995-05-26 1996-11-28 Diacrin, Inc. Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function
ATE408417T1 (de) * 2000-01-25 2008-10-15 Univ Nebraska Für die transplantation präparierte organe und abstossungsresistenz
WO2001065934A2 (en) * 2000-03-09 2001-09-13 Lee Walters Applications of immune system tolerance to treatment of various diseases
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
CA2416877C (en) * 2000-07-27 2013-03-12 Apogene Gmbh & Co. Kg Somatic cloning gene transfer for producing recombinant proteins, cells and organs
US20030096016A1 (en) * 2001-09-07 2003-05-22 Yeda Research And Development Co. Ltd. Methods of kidney transplantation utilizing developing nephric tissue
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
JP2005523328A (ja) * 2002-04-19 2005-08-04 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 胎盤由来の幹細胞及びその使用
US20040161419A1 (en) * 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
AU2005290849B2 (en) * 2004-10-04 2009-09-03 Yeda Research And Development Co. Ltd. Disease treatment via developing non-syngeneic graft transplantation
US20060148080A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Methods for supporting and producing human cells and tissues in non-human mammal hosts
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
WO2006113220A2 (en) * 2005-04-13 2006-10-26 Ximerex, Inc. Transgenic mammals expressing human preproinsulin
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
WO2010047676A1 (en) * 2008-10-20 2010-04-29 Yangxin Fu An immunocompetent xenograft model
US8263823B2 (en) * 2008-10-20 2012-09-11 Adimmu Institute Inc. Immunocompetent xenograft model
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2012092663A1 (en) * 2011-01-04 2012-07-12 Network Immunology Inc. Monoclonal anti-anti-anti-mhc antibodies and uses thereof
WO2015061550A1 (en) * 2013-10-24 2015-04-30 Kansas State University Research Foundation Immune competent models of human disease
SG11202002118XA (en) * 2017-09-19 2020-04-29 Univ Meiji Method for developing organ that lacks specific functional cell

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
EP0031812B1 (de) * 1979-03-27 1983-06-15 National Research Development Corporation Verbesserungen an immunologischen zusammensetzungen
US4624917A (en) * 1982-02-17 1986-11-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for the production of human T-cell growth factor
JPS6339820A (ja) * 1986-08-05 1988-02-20 Kingo Yoshida 拒絶反応抑制，幼若細胞移植による不老長寿法
JPS63170322A (ja) * 1986-12-30 1988-07-14 Kingo Yoshida 幼若臓器・器管・組織移植による延命長寿法
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
JPH01132528A (ja) * 1987-11-19 1989-05-25 Kingo Yoshida 母体胎児免疫抑制を応用した若細胞移植による不老長寿法並びに病気治療法
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0484512A4 (en) * 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
CA2124858A1 (en) * 1991-11-05 1993-05-13 Samuel Strober Suppressor and progenitor cells

Also Published As

Publication number Publication date
DE69431107D1 (de) 2002-09-05
WO1994027622A1 (en) 1994-12-08
AU7044594A (en) 1994-12-20
EP0700297A4 (de) 1997-04-09
CA2163517A1 (en) 1994-12-08
JP4236279B2 (ja) 2009-03-11
EP0700297B1 (de) 2002-07-31
CA2163517C (en) 2011-03-15
JPH09500618A (ja) 1997-01-21
EP0700297A1 (de) 1996-03-13
ATE221382T1 (de) 2002-08-15
AU693452B2 (en) 1998-07-02
US6060049A (en) 2000-05-09

Similar Documents

Publication Publication Date Title
DE69431107T2 (de) Die erzeugung von toleranz gegen fremdtransplantate durch tolerogenese mit hilfe von ersatzlebewesen
Lee et al. Human antibody recognition of xenogeneic antigens (NeuGc and Gal) on porcine heart valves: could genetically modified pig heart valves reduce structural valve deterioration?
Hara et al. Allosensitized humans are at no greater risk of humoral rejection of GT‐KO pig organs than other humans
IL113238A0 (en) Alpha (1,3) Galactosyltransferase negative swine
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
Matthews The development of the Starr-Edwards heart valve.
EP0661980A4 (de) Verfahren und zusammensetzungen zur hinderung der antikörper-vermittelten abstossung von xenogener transplantaten.
IS1793B (is) Notkun á kítósan og fjölsykru í tengslum við endurmyndun á hörðum vef, ásamt ígræðlingi
ATE424164T1 (de) Verfahren zur herstellung einer gefässprothese
CA2486759A1 (en) Universal chimera bank
Yamada et al. N-acetyl cysteine improves affinity of beta-tricalcium phosphate granules for cultured osteoblast-like cells
Schneider et al. Rolling adhesion of human NK cells to porcine endothelial cells mainly relies on CD49d-CD106 interactions1
Schneider et al. Adhesive interactions between human NK cells and porcine endothelial cells
DK0728016T3 (da) Anvendelse af anti-idiotypiske antistoffer til forebyggelse af hyperakut afstødning af xenotransplantater
Abdolghafoorian et al. Effect of heart valve decellularization on xenograft rejection
Lang et al. Long-term viability of transplanted ossicles
Bourdeaux et al. Liver retransplantation in children. A 21‐year single‐center experience
ATE259235T1 (de) Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene
Park et al. Effects of reduction in the alpha‐gal antigen on bony union: a model of xenobone graft using GalT knockout mouse
Kim et al. Immunological Compatibility of Bone Tissues from Alpha‐1, 3‐galactosyltransferase Knockout Pig for Xenotransplantation
Manka The Role of Mary in the Infancy Narrative of Luke
McGregor et al. Biological equivalence of GGTA-1 Glycosyltransferase knockout and standard porcine pericardial tissue using 90-day mitral valve implantation in adolescent sheep
Kawalec-Carroll et al. Immunogenicity of unprocessed and photooxidized bovine and human osteochondral grafts in collagen-sensitive mice
Singh et al. Long-term allograft survival in renal transplantation from elderly donors
ATE283063T1 (de) Allogene und xenogene transplantation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PUSCHMANN & BORCHERT, 82041 OBERHACHING

8339 Ceased/non-payment of the annual fee